Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

L. Simpson, Eric; Bieber, Thomas; Guttman‐Yassky, Emma; A. Beck, Lisa; Blauvelt, Andrew; J. Cork, Michael; I. Silverberg, Jonathan; Deleuran, Mette; Kataoka, Yoko; Lacour, J.‐P.; Kingo, Külli; Worm, Margitta; Poulin, Yves; Wollenberg, Andreas; Soo, Yuhwen; M.H. Graham, Neil; Pirozzi, Gianluca; Akinlade, Bolanle; Staudinger, Heribert; Mastey, Vera; Eckert, Laurent; Gadkari, Abhijit; Stahl, Neil; D. Yancopoulos, George; Ardeleanu, Marius

doi:10.1056/nejmoa1610020

Public

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Published in New England Journal of Medicine • Oct 1, 2016

Authors:

Eric L. Simpson

Thomas Bieber

Emma Guttman‐Yassky

Abstract

BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, ph...

Subject

Dupilumab

Atopic dermatitis

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!